GCS-100
Sponsors
La Jolla Pharmaceutical Company
Conditions
Chronic Kidney DiseaseChronic Lymphocytic LeukemiaDiabetic Chronic Kidney DiseaseDiffuse Large B-cell LymphomaMultiple Myeloma
Phase 1
Safety and Efficacy Study of GCS-100LE in the Treatment of Multiple Myeloma
TerminatedNCT00609817
Start: 2008-05-31End: 2009-04-30Updated: 2013-06-25
GCS-100LE in Combination With Etoposide and Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
WithdrawnNCT00776802
Start: 2008-07-31End: 2009-04-30Updated: 2013-06-25
Safety Study of GCS-100 to Treat Chronic Kidney Disease
CompletedNCT01717248
Start: 2013-01-31End: 2013-06-30Updated: 2013-06-20
Phase 2
Study of the Safety of GCS-100 in Subjects With Chronic Lymphocytic Leukemia
CompletedNCT00514696
Start: 2007-02-28End: 2009-04-30Updated: 2013-06-17
A Phase 2a Study of Weekly Doses of GCS-100 in Patients With Chronic Kidney Disease
CompletedNCT01843790
Start: 2013-06-30End: 2014-09-30Updated: 2015-09-01
A Phase 2 Extension Study of Study GCS-100-CS-4002
CompletedNCT02155673
Start: 2014-01-31End: 2016-06-30Updated: 2016-12-26
A Phase 2b Study of GCS-100 in Patients With Chronic Kidney Disease Caused by Diabetes
NCT02312050
Start: 2015-03-31End: 2016-12-31Target: 375Updated: 2015-05-19
A Phase 2 Extension of Study GCS-100-CS-4003
WithdrawnNCT02333955
Start: 2015-01-31End: 2016-07-31Updated: 2015-01-15